Home World News Pelabresib Plus Ruxolitinib Improves Signs of Underlying Myelofibrosis Pathobiology and Provides Clinical... World News Pelabresib Plus Ruxolitinib Improves Signs of Underlying Myelofibrosis Pathobiology and Provides Clinical Benefit Over JAK Inhibitor Monotherapy By Ogkologos - March 25, 2025 970 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MANIFEST-2 study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Qué debo saber sobre los programas de emparejamiento de ensayos clínicos... November 28, 2023 Patient Guide in Bladder Cancer Now Available Also in Italian November 28, 2025 ESMO 2022: New Research in Treating Gastrointestinal and Genitourinary Cancers November 10, 2022 Cancer in My Community: Addressing Regional Cancer Disparities in Peru August 24, 2023 Load more HOT NEWS Sex, intimacy and cancer – That Cancer Conversation FDA Grants Accelerated Approval to Zanubrutinib for Relapsed or Refractory Follicular... Our new strategy to make discoveries, drive progress, and bring hope Maintenance Regorafenib Significantly Delays Disease Progression After First-Line Treatment in Patients...
